A data-backed comparison from GLP Chart matches CMS acquisition costs to verified consumer cash prices, revealing large channel and packaging price gaps for GLP-1 drugs.
GLP Chart’s weekly verification method produced a panel median all-in monthly price of $348 across 11 GLP-1 telehealth programs for August 2026.
Packaging differences produce large price spreads: Lilly’s Zepbound single-dose pens carry a higher pharmacy acquisition cost than the multi-dose KwikPen equivalent.
GLP Chart publishes its data and method (CSV/JSON) at glpchart.com/price-index and releases updates on the first Tuesday of each month.
John Samaras of GLP Chart compares two public price streams and finds large, concrete gaps between what pharmacies pay wholesalers and what cash-paying consumers pay at retail. He uses CMS National Average Drug Acquisition Cost (NADAC) files for acquisition costs and weekly verified consumer prices for the cash channel.
Zepbound: at 15 mg, pharmacies pay $672 per month for the multi-dose KwikPen versus $1,051 per month for single-dose pens — a 1.56x spread (difference $379). At the 2.5 mg starting dose the spread was larger. The only documented difference is container format.
Samaras documents a repeatable weekly method: check each program's published all-in maintenance monthly price every Monday, record the figure (not introductory or prorated prepaid rates), and build an index. The panel is fixed so changes reflect price moves rather than sample changes. GLP Chart keeps dated URLs and numbered revisions and publishes CSV/JSON at glpchart.com/price-index under CC BY 4.0.
The public lacks routine side-by-side reporting of acquisition costs and consumer cash prices. Without weekly records, reported price cuts or increases lack context. This comparison clarifies how different commercial channels and product packaging can produce materially different prices for the same active drug.
Samaras' work turns two separate public data streams into a usable comparison: NADAC acquisition costs versus verified cash prices. The result exposes thousands-of-dollars channel gaps and packaging-driven spreads, and it provides a replicable, dated method for ongoing tracking.
This is an interesting look at the gap between what pharmacies pay and what patients ultimately pay for medications. The pricing differences highlight how complicated the healthcare system can be, <a href="https://www.in-focus.com.sg/marriage-counselling-therapy/" rel="nofollow ugc">couple counselling in Singapore</a>
By JOHN SAMARAS A US retail pharmacy pays $1,302 to acquire one month of branded Wegovy. That figure comes from the Centers for Medicare and Medicaid Services National Average Drug Acquisition Cost Continue reading...
Three federal pricing changes are about to land on a single outpatient claim. The largest infusion and oncology programs will feel them first, and hardest. Most of the 340B debate centers on rural hospitals and community health centers. The biggest dollars, however, sit with academic medical centers (AMCs) and large he
An analysis of commercial claims for 106 physician-administered outpatient drugs suggests $101 of additional plan spending per member per year stemming from site-of-treatment pay differences.
The following is a guest article by Casey Williams, SVP of Patient Engagement at RevSpring Healthcare affordability debates tend to focus on the price of care: what procedures cost, what insurers cover, and what patients owe. That conversation matters, but it skips an issue providers can address right now, which is tha
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.